Analyst firms · Needham · ACAD
Needham ACAD price target and rating history
ACADIA Pharmaceuticals Inc. (ACAD) · Health Care
Needham rates ACADIA Pharmaceuticals Inc. (ACAD) Buy with a $32 price target, as of its latest action on Mar 12, 2024. It has published 4 rating actions on ACAD since August 2021, including 1 upgrade and 0 downgrades. Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.
- Current rating
- Buy
- Price target
- $32
- Median target, all firms
- $31
- Actions on ACAD
- 4
Needham price target on ACAD
Every Needham rating on ACAD
- Mar 12, 2024
- Jan 24, 2024
- Sep 23, 2021
- Aug 5, 2021
How other firms rate ACAD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $23 | Oct 13, 2026 |
| BofA Securities | Buy | $29 | Mar 25, 2026 |
| Wolfe Research | Outperform | $33 | Feb 24, 2026 |
| Mizuho | Outperform | $35 | Feb 23, 2026 |
Questions about Needham and ACAD
- What is Needham's price target for ACAD?
- Needham's latest stated price target for ACADIA Pharmaceuticals Inc. (ACAD) is $32, from its action on Mar 12, 2024.
- What is Needham's rating on ACAD?
- Needham rates ACAD Buy, a bullish rating, as of Mar 12, 2024.
- When did Needham last change its view on ACAD?
- On Mar 12, 2024, Needham cuts its price target to $32 from $36, keeps Buy.
- How does Needham's ACAD target compare with other analysts?
- Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.
More ACAD rating histories
All Needham ratingsACAD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.